Berlor is a generic antiplatelet drug called P2Y12.
Indications for Berlor include prevention and reduction of the risk of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome, and prevention of stent clotting in patients undergoing angioplasty.
Since the inalienable right of every Iranian patient is to consume quality medicine, Kimiara Company, in order to achieve this goal in order to support patients, has produced its Tikaglorur drug under the Berlor brand, according to the highest international standards.
Raw materials and formulations TikaGlor is produced by the most powerful raw material supplier in the world called MSN. The TikaGlor product line in this company is approved by the US Food and Drug Administration and the European GMP. MSN company is ranked first in terms of the number of drug cases in the US and is one of the top 17 generic pharmaceutical companies in the world.
Another indicator of proof of Berlor quality is the efficacy and safety of this drug similar to its original brand, Astraznica’s Brillinta, which has been proven in bioequivalence studies. Citing the quality of the raw material, formulation, production line of this drug as well as bioequivalence studies, Berlor with the highest quality is a reliable alternative to its main brand in Iran.